NASDAQ:DNLI Denali Therapeutics Q3 2025 Earnings Report $22.28 -0.52 (-2.28%) As of 09/4/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Denali Therapeutics EPS ResultsActual EPS-$0.74Consensus EPS -$0.76Beat/MissBeat by +$0.02One Year Ago EPS-$0.63Denali Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$1.00 millionBeat/MissN/AYoY Revenue GrowthN/ADenali Therapeutics Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time7:00AM ETUpcoming EarningsDenali Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Denali Therapeutics Earnings HeadlinesDenali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 2, 2026 | americanbankingnews.comDenali’s DNL921 Trial: Early Alzheimer’s Safety Data That Could Shape Long-Term UpsideAugust 20, 2026 | tipranks.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 6 at 1:00 AM | Chaikin Analytics (Ad)Denali Therapeutics: Bullish On Avlayah And Their ProspectsAugust 19, 2026 | seekingalpha.comDenali Therapeutics (DNLI) Q2 2026 Earnings Call TranscriptAugust 13, 2026 | finance.yahoo.comDenali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial OneAugust 13, 2026 | seekingalpha.comSee More Denali Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Denali Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Denali Therapeutics and other key companies, straight to your email. Email Address About Denali TherapeuticsDenali Therapeutics (NASDAQ:DNLI) is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients. The company is also advancing modulators of progranulin for frontotemporal dementia and exploring novel approaches to lysosomal storage disorders. Denali has entered strategic collaborations with established industry partners to accelerate clinical development, most notably with Biogen for Alzheimer’s and Sanofi for lysosomal programs. Founded in 2015 by industry veteran Stefan Oehlén and headquartered in South San Francisco, Denali maintains research sites in Cambridge, Massachusetts, and has expanded its organization to support global clinical trials. The company went public in 2019, and its leadership is led by Chief Executive Officer Ryan Watts, whose background in finance and biotech supports Denali’s capital strategy and pipeline advancement. Denali Therapeutics conducts its research and clinical operations primarily in the United States while pursuing regulatory approvals and trial sites globally. The company’s goal is to address unmet needs in neurodegeneration by bringing forward differentiated therapies that can slow or stop disease progression, offering new hope for patients and families affected by these challenging disorders.View Denali Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/31 - 09/04Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key SignalLululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround StorySnowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityGitLab’s AI Tools Are Starting to Turn Developer Demand Into Real RevenueMerchants Bancorp’s Rally Is Testing How Much Risk Investors Will Overlook Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
